Proteomic studies on apoB‐containing lipoprotein in cardiovascular research: A comprehensive review

Gianazza, Erica; Zoanni, Beatrice; Mallia, Alice; Brioschi, Marcos Leal; Colombo, Gualtiero I.; Banfi, Cristina

doi:10.1002/mas.21747

Cited by 6 publications

(2 citation statements)

References 129 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Plasma lipoproteins are complex macromolecules composed of lipids and proteins which are classified into subclasses based on their size (5 nm up to 1200 nm) and density (0.930-1.20 g/mL) [1]. Of the several classes of lipoproteins [61], HDL are of utmost importance for lipid homeostasis and additionally have multiple protective effects [62]. HDL are naturally classified as nanoparticles in circulation, given their nanoscale size of 5-12 nm, with a density ranging from 1.063 to 1.21 g/mL.…”

Section: High-density Lipoproteins Are Self-assembling Nanoparticlesmentioning

confidence: 99%

A Current Update on the Role of HDL-Based Nanomedicine in Targeting Macrophages in Cardiovascular Disease

Rani

Marsche

2023

Pharmaceutics

View full text Add to dashboard Cite

High-density lipoproteins (HDL) are complex endogenous nanoparticles involved in important functions such as reverse cholesterol transport and immunomodulatory activities, ensuring metabolic homeostasis and vascular health. The ability of HDL to interact with a plethora of immune cells and structural cells places it in the center of numerous disease pathophysiologies. However, inflammatory dysregulation can lead to pathogenic remodeling and post-translational modification of HDL, rendering HDL dysfunctional or even pro-inflammatory. Monocytes and macrophages play a critical role in mediating vascular inflammation, such as in coronary artery disease (CAD). The fact that HDL nanoparticles have potent anti-inflammatory effects on mononuclear phagocytes has opened new avenues for the development of nanotherapeutics to restore vascular integrity. HDL infusion therapies are being developed to improve the physiological functions of HDL and to quantitatively restore or increase the native HDL pool. The components and design of HDL-based nanoparticles have evolved significantly since their initial introduction with highly anticipated results in an ongoing phase III clinical trial in subjects with acute coronary syndrome. The understanding of mechanisms involved in HDL-based synthetic nanotherapeutics is critical to their design, therapeutic potential and effectiveness. In this review, we provide a current update on HDL-ApoA-I mimetic nanotherapeutics, highlighting the scope of treating vascular diseases by targeting monocytes and macrophages.

show abstract

Section: High-density Lipoproteins Are Self-assembling Nanoparticlesmentioning

confidence: 99%

A Current Update on the Role of HDL-Based Nanomedicine in Targeting Macrophages in Cardiovascular Disease

Rani

Marsche

2023

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…E3 and E4 in class E. So far, more than 20 Apos have been found [26][27][28] . In addition to the above mentioned, classical Apos also contain Apo F, Apo H, Apo J, Apo M and so on.…”

Section: Introductionmentioning

confidence: 99%

Apolipoproteins as potential communicators play an essential role in the pathogenesis and treatment of early atherosclerosis

Li,

Luo,

Hua

et al. 2023

Int. J. Biol. Sci.

View full text Add to dashboard Cite

Atherosclerosis as the leading cause of the cardiovascular disease is closely related to cholesterol deposition within subendothelial areas of the arteries. Significantly, early atherosclerosis intervention is the critical phase for its reversal. As atherosclerosis progresses, early foam cells formation may evolve into fibrous plaques and atheromatous plaque, ulteriorly rupture of atheromatous plaque increases risks of myocardial infarction and ischemic stroke, resulting in high morbidity and mortality worldwide. Notably, amphiphilic apolipoproteins (Apos) can concomitantly combine with lipids to form soluble lipoproteins that have been demonstrated to associate with atherosclerosis. Apos act as crucial communicators of lipoproteins, which not only can mediate lipids metabolism, but also can involve in pro-atherogenic and anti-atherogenic processes of atherosclerosis via affecting subendothelial retention and aggregation of low-density lipoprotein (LDL), oxidative modification of LDL, foam cells formation and reverse cholesterol transport (RCT) in macrophage cells. Correspondingly, Apos can be used as endogenous and/or exogenous targeting agents to effectively attenuate the development of atherosclerosis. The article reviews the classification, structure, and relationship between Apos and lipids, how Apos serve as communicators of lipoproteins to participate in the pathogenesis progression of early atherosclerosis, as well as how Apos as the meaningful targeting mass is used in early atherosclerosis treatment.

show abstract

Apolipoprotein B compared with low-density lipoprotein cholesterol in the atherosclerotic cardiovascular diseases risk assessment

Galimberti

Casula

Olmastroni

2023

Pharmacological Research

View full text Add to dashboard Cite

Proteomic studies on apoB‐containing lipoprotein in cardiovascular research: A comprehensive review

Cited by 6 publications

References 129 publications

A Current Update on the Role of HDL-Based Nanomedicine in Targeting Macrophages in Cardiovascular Disease

A Current Update on the Role of HDL-Based Nanomedicine in Targeting Macrophages in Cardiovascular Disease

Apolipoproteins as potential communicators play an essential role in the pathogenesis and treatment of early atherosclerosis

Apolipoprotein B compared with low-density lipoprotein cholesterol in the atherosclerotic cardiovascular diseases risk assessment

Contact Info

Product

Resources

About